MOD Pizza to Celebrate the Opening of its New Coral Springs, Florida Location on February 6th

FORT LAUDERDALE, FL—(Marketwired – February 05, 2018) – (NYSE: BBX) (OTCQX: BBXTB) BBX Capital Corporation today announced that the grand opening celebration of its newest MOD Pizza (“MOD”) location will begin at 12 pm on Tuesday, February 6th, at 2702 N. University Drive, in The Walk, in Coral Springs, Florida.

BBX Capital is the exclusive franchisee for the MOD Pizza brand in the state of Florida.

In celebration of the store's grand opening, MOD will be offering a free artisan–style pizza to the first 52 guests that attend. After that, 100% of all pizza sales on opening day will be donated to the Coral Springs Museum of Art*.

“MOD offers consumers an authentic, affordable and fast dining experience,” said Jarett Levan, President of BBX Capital. “We are very pleased to open MOD Pizza in Coral Springs, our second location in Broward County, and to introduce the community to our artisan–style pizzas, 30+ toppings, one price, and the superfast MOD experience.”

MOD's individual, artisan–style pizzas are made on demand using fresh–pressed dough and signature sauces. Customers create their own pizzas and salads using any combination of over 30 featured toppings, or they can choose from a menu of MOD classics. The price always remains the same — $7.97 — regardless of the number of toppings. Pizzas are hand–cooked in an 800–degree oven in just minutes and salads are individually hand–tossed for each customer. The menu is rounded out with handspun milkshakes, house–made lemonades and iced teas, and local craft beers and wine. Hours of operation will be Monday through Sunday from 10:30am to 10:00pm.

To learn more about MOD, please visit or watch the MOD Difference Video.

* The Coral Springs Museum of Art's mission is to create a stimulating and enjoyable educational visual arts experience for the South Florida community, exhibiting diverse Florida, national and international artists. For further information, please see visit

About MOD Super–Fast Pizza Holdings, LLC:
MOD Pizza is a pioneer of the fast–casual pizza segment, founded in Seattle in 2008 by entrepreneur husband and wife team Scott and Ally Svenson. MOD's individual artisan–style pizzas are made on demand, allowing customers to create their own pizzas and salads, using fresh–pressed dough, signature sauces and over 30 toppings, all for one incredible price. With more than 300 locations system–wide across 27 states and the United Kingdom, MOD is committed to creating not only a cool place to eat, but an inspired place to work. The company was recently recognized as the number one mid–sized restaurant chain in the US in the October 2017 Fishbowl Buzz Brands Report, named as the most loved pizza brand by Foodable Network in its May 2017 Most Loved Brands Report, has been ranked as America's fastest growing chain restaurant by Technomic, earned a spot on the Inc. 500 list, and was recognized by Fortune as one of the “20 Best Workplaces in Retail,” a “Best Workplace for Women,” a “Best Workplace for Millennials,” and a “Best Workplace for Diversity.” For more information, please visit or connect with the brand via Facebook, Twitter or Instagram.

BBX Capital is the exclusive franchisee for the MOD Pizza brand in the state of Florida and has signed an agreement to develop up to 60 MOD locations throughout the state over the next six years. In 2017, BBX Capital opened MOD locations in Parkland and Jacksonville, and has plans to open in Kendall in the first quarter of 2018.

About BBX Capital:
BBX Capital Corporation (NYSE: BBX) (OTCQX: BBXTB), is a diversified holding company whose activities include its MOD Pizza franchises, its approximate 90 percent ownership interest in Bluegreen Vacations Corporation (NYSE: BXG) as well as its Real Estate and Middle Market Divisions. For more information, please visit

Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th

AUSTIN, TX—(Marketwired – February 05, 2018) – Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the 20th Annual BIO CEO & Investor Conference on Monday, February 12th, 2018 at 3:00 p.m. Eastern Time at the New York Marriott Marquis Hotel in New York.

Interested parties can access a live audio webcast on the Savara web site at An archived presentation will be available on the web site for 30 days.

About Savara
Savara Inc. is a clinical–stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life–threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, an inhaled granulocyte–macrophage colony–stimulating factor, or GM–CSF, in Phase 3 development for pulmonary alveolar proteinosis, or PAP, and in preparation for Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection; AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for heart failure with preserved ejection fraction, or HFpEF, in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best–in–class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at (Twitter: @SavaraPharma)

Savara may announce material information about its finances, product candidates, clinical trials and other matters to its investors using its investor relations website (, SEC filings, press releases, public conference calls and webcasts. Savara uses these channels, as well as social media, to communicate with its stockholders and the public about the company and other issues. It is possible that the information Savara posts on its website and social media could be deemed to be material information. Therefore, Savara encourages investors, the media, and others interested in the company to review the information Savara posts on its investor relations website (referenced above) and any social media channels listed on its website from time to time.

ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor

MADRID, SPAIN and CAMBRIDGE, MA—(Marketwired – February 05, 2018) – Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical–stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today another key addition to its Scientific Advisory Board (SAB) to reinforce its development capabilities for its epigenetic drug ORY–1001 in leukemia and solid tumors with the appointment of Dr. Lori A. Kunkel.

“Dr. Kunkel has an extraordinary track record in the development of clinical and regulatory strategies resulting in the global commercialization of successful hemato–oncology and immuno–oncology products. She brings strong industry–leading expertise and deep knowledge in oncology drug development that will play a critical role in the development of our epigenetic pipeline as the company is committed to advancing the development of ORY–1001 in hemato–oncology and some solid tumors,” said Carlos Buesa, President and CEO of ORYZON.

Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Kunkel began her career in industry as a clinical scientist at Genentech working on the development of RITUXAN®. Dr. Kunkel presently serves on the Board of Directors of Loxo Oncology, Curis, Inc, Tocagen and Maverick Therapeutics. She was previously the acting Chief Medical Officer at Loxo and she served as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc (acquired by Onyx Pharmaceuticals), contributed to the approvals of cancer therapeutics IMBRUVICA® and KYPROLIS®, respectively. She has advised multiple clients including Chiron (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene), Stemcentrx, Inc (acquired by Abbvie), Amphivena Therapeutics, Atreca, Inc and Verastem, Inc.

Dr. Kunkel served as a faculty member in the Division of Hematology/Oncology at University of California, Los Angeles. Dr. Kunkel obtained a medical degree from University of Southern California and a bachelor's degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.

“I am excited to work with the management team to help advance the ORY–1001 program forward as a potential treatment for patients with leukemia as well as their other programs,” said Dr. Kunkel. “Oryzon is working towards addressing significant unmet medical needs and I look forward to being a part of their efforts.”

About ORY–1001
ORY–1001 is a highly potent and selective oral epigenetic inhibitor that modulates LSD1, a histone demethylase that removes (“erases”) signals in the histone, provoking changes in the reading context of the chromosome and turning off genes. Aberrant “erasing” activity may lead to disease. LSD1 has been related with several malignancies such as solid tumors and hematological diseases. In Acute Myeloid Leukemia (AML) ORY–1001 affects AML stem cells, a sub–population of cancer cells that has been proposed to be responsible for frequent relapses of the disease. ORY–1001 also significantly reduces tumor cell load and increases survival time in mouse models of Acute Lymphoblastic Leukemia. LSD1 inhibition has been proposed as a meaningful therapeutic option, alone or in combination, in several solid tumors such as Small cell lung cancer (SCLC). In a First in Man Phase I–IIA study in relapsed–refractory AML patients ORY–1001 was safe and well tolerated and produced a clear proof of biological concept as a differentiating agent with 29% (12/41) of all patients showing some degree of anti–leukemic clinical activity including one CRi in a selected patient subgroup.

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has resulted in + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case by–case basis to either keep the development in–house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Spain and USA. For more information, visit

This communication contains forward–looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward–looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward–looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward–looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward–looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward–looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward–looking statements, which speak only as of the date they were made. All subsequent oral or written forward–looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward–looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward–looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

Advanced Proteome Therapeutics Announces New Patent Grant

VANCOUVER, BC—(Marketwired – February 05, 2018) – Advanced Proteome Therapeutics Corporation (“APC” or the “Company“) (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC's Japanese Patent Application No. :2015–511804, titled “Site specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.

The present invention relates to the formation of conjugates from proteins, chemically modified for linkage to anticancer drugs, with affinities to biomarkers on cancer cell surfaces. It provides and specifies new compositions, methods and combinations for tumor, and tumor vasculature targeting and cancer treatment.

“We are excited to announce the Japanese Patent Office has granted us this patent,” commented Randal Chase, CEO of Advanced Proteome Therapeutics. “This patent represents additional opportunities beyond just the North American market for advancing our relationships with the global biotech and pharmaceutical communities.”

This patent is one of a series of filings by APC covering technology and compositions related to the development of new anticancer therapies.


Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward–looking statements relating to the Company's business, which can be identified by the use of forward–looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company's strategies, plans or intentions. Such forward–looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward–looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward–looking statements. We disclaim any obligation to update any such forward–looking statements to reflect future events or developments.